Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...
Pfizer (PFE) recently reported a revenue decline tied to weaker COVID product sales and a US$4.4b impairment charge, while ...
Zacks Investment Research on MSN
Pfizer Inc. (PFE) is attracting investor attention: Here is what you should know
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
Hosted on MSN
Pfizer's 7% Dividend: Income Gem or Value Trap?
Pfizer's 7% dividend yield ranks among the highest in the healthcare sector, nearly triple the average of the S&P 500. The payout ratio has improved to 89% from over 100% in recent quarters, but ...
Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...
Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...
Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...
Pfizer (NYSE: PFE) has become the dividend investor's siren song. With shares down 31% over the past five years and a current yield of 7%, the pharmaceutical giant offers one of the juiciest payouts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results